Synaptic degeneration in Alzheimer disease
Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …
individuals accompanied by the presence of two pathological protein aggregates—amyloid …
The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
D Jeremic, L Jiménez-Díaz, JD Navarro-López - Ageing research reviews, 2021 - Elsevier
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
C Haass, D Selkoe - PLoS biology, 2022 - journals.plos.org
Strong genetic evidence supports an imbalance between production and clearance of
amyloid β-protein (Aβ) in people with Alzheimer disease (AD). Microglia that are potentially …
amyloid β-protein (Aβ) in people with Alzheimer disease (AD). Microglia that are potentially …
Phosphorylated tau in Alzheimer's disease and other tauopathies
Alzheimer's disease (AD) is the leading cause of dementia in elderly people. Amyloid beta
(Aβ) deposits and neurofibrillary tangles are the major pathological features in an …
(Aβ) deposits and neurofibrillary tangles are the major pathological features in an …
[HTML][HTML] Anti-amyloid immunotherapies for Alzheimer's disease: a 2023 clinical update
G Yadollahikhales, JC Rojas - Neurotherapeutics, 2023 - Elsevier
The amyloid cascade hypothesis is a useful framework for therapeutic development in
Alzheimer's disease (AD). Amyloid b 1-42 (Aβ) has been the main target of experimental …
Alzheimer's disease (AD). Amyloid b 1-42 (Aβ) has been the main target of experimental …
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease
Abstract Development of tau-based therapies for Alzheimer's disease requires an
understanding of the timing of disease-related changes in tau. We quantified the …
understanding of the timing of disease-related changes in tau. We quantified the …
[HTML][HTML] Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease
H Zhang, W Wei, M Zhao, L Ma, X Jiang… - … journal of biological …, 2021 - ncbi.nlm.nih.gov
Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …
Stress granules and neurodegeneration
Recent advances suggest that the response of RNA metabolism to stress has an important
role in the pathophysiology of neurodegenerative diseases, particularly amyotrophic lateral …
role in the pathophysiology of neurodegenerative diseases, particularly amyotrophic lateral …
[HTML][HTML] Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy
T Wu, B Dejanovic, VD Gandham, A Gogineni… - Cell reports, 2019 - cell.com
Complement pathway overactivation can lead to neuronal damage in various neurological
diseases. Although Alzheimer's disease (AD) is characterized by β-amyloid plaques and tau …
diseases. Although Alzheimer's disease (AD) is characterized by β-amyloid plaques and tau …